Other
MDS
0
Pipeline Programs↗
12
Active Trials↗
12
Companies Involved↗
MDS is an early-stage landscape with 0 programs across 12 companies. The most active players are EMD Serono Research & Development Institute, Inc., Shanghai Bensen Pharmaceutical Co., Ltd., Jasper Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
37
clinical trials
Completed10 · 27%
Terminated8 · 22%
Recruiting6 · 16%
Unknown status5 · 14%
Active, not recruiting4 · 11%
Not yet recruiting2 · 5%
Other2 · 5%
Clinical Trials
Trial Activity
37 trials
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Recruiting·—·Phase 2·NCT07238686·40 enrolled
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Active, not recruiting·—·Phase 1·NCT03974217·13 enrolled
HCT With PTCy in Higher-risk MDS
Active, not recruiting·—·Phase 2·NCT06098313·113 enrolled
CyFluATG in Lower Risk MDS
Active, not recruiting·—·Phase 2·NCT06098326·30 enrolled
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04798339·13 enrolled
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07400341·66 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)